[Incidence, laboratory diagnosis and serologic prediction of hemolytic disease of newborn infants due to ABO incompatibility].
The frequency of the haemolytic disease of the newborn due to ABO-incompatibility (ABO-HDN), requiring treatment, is with approximately 5% of all hyperbilirubinemias in newborns lower than usually expected. Contrary to common conception the serologic diagnosis of ABO-HDN by means of the direct antiglobulin test (DAT) is possible with satisfactory accuracy. The enormous laboratory burden of IgG-anti-A, -B testing during pregnancy is in poor conformity with clinically demonstrable illness. This discrepancy is due to the rarity of true ABO incompatibilities and not to the ineffectiveness of laboratory investigations.
D000017:ABO Blood-Group System / Q000276:immunology*; D001317:Austria; D001787:Blood Group Incompatibility / Q000097:blood / Q000150:complications*; D003298:Coombs Test; D004899:Erythroblastosis, Fetal / Q000097:blood / Q000453:epidemiology / Q000276:immunology*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007567:Jaundice, Neonatal / Q000276:immunology; D011247:Pregnancy; D011296:Prenatal Diagnosis; D011379:Prognosis
D000017:ABO Blood-Group System
Frequenz, Laboratoriumsdiagnostik und serologische Voraussage des ABO-bedingten Morbus hämolyticus neonatorum.